newsfilter
← Latest News
Business Wire·

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Phase 1 study in patients with mCRPC expected to begin enrollment in the fourth quarter of 2026 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta